The Smiling Heretic
By Daniel S. Levine,
The Journal of Life Sciences
| 05. 16. 2008
[Quotes CGS's Marcy Darnovsky]
Reg Kelly has an infectious smile that seems to be part childlike wonder and part wise guy. The fun, though, is in listening to Kelly talk. His words come in enthusiastic bursts, coated in a Scottish accent that makes everything he says seem just a tad more colorful. And what he says conveys just enough distaste for authority to give him what amounts to, in the bureaucratic world of academia, a bad-boy edge.
But when it's suggested to the head of California's Institute for Quantitative Biosciences, or QB3, that his charm might be what makes him so effective at raising money, negotiating deals with corporate partners, and circumventing institutional barriers, he is quick to correct. "It's not charm," Kelly says. "What it is, is the belief that this is worth doing. It's the passion. We have a very clear vision, and people like that."
QB3 is one of four California Institutes for Science and Innovation established in 2000 by then-Governor Gray Davis. Headquartered at the Mission Bay campus of the University of California, San Francisco, QB3 extends across three University...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...